Amneal Reports Q1 Revenue of $723M, Beats Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 22 2026
0mins
Should l Buy AMRX?
Reports Q1 revenue $723M, consensus $720.52M. "Amneal delivered a very strong start to 2026, reflecting the strength of our diversified business and multiple growth drivers across the portfolio. Our Specialty business continues to perform exceptionally well, led by CREXONT and the recent launch of BREKIYA autoinjector, alongside a strong cadence of key launches in Affordable Medicines. We are entering the Kashiv transaction from a position of strength, at a time when we see an extended period of accelerated growth ahead with no shortage of opportunities across our core businesses. Combined with our very strong Q1 results, we are pleased to increase our FY26 guidance," said Chirag and Chintu Patel, Co-Founders and Co-CEO of Amneal.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMRX
Wall Street analysts forecast AMRX stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 12.870
Low
13.00
Averages
14.33
High
15.00
Current: 12.870
Low
13.00
Averages
14.33
High
15.00
About AMRX
Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Amneal Pharmaceuticals Q1 Earnings Preview
- Earnings Announcement: Amneal Pharmaceuticals (AMRX) is set to release its Q1 2026 earnings on May 1 before market open, with consensus EPS estimate at $0.17, reflecting a 19% year-over-year decline, while revenue is projected at $716.78 million, indicating a 3.1% year-over-year increase.
- Historical Performance: Over the past two years, AMRX has exceeded EPS estimates 88% of the time and revenue estimates 75% of the time, demonstrating a degree of stability and reliability in its financial performance.
- Estimate Adjustments: In the last three months, there have been no upward revisions to EPS estimates, with three downward adjustments, while revenue estimates also saw no upward revisions and two downward adjustments, indicating a cautious market outlook on the company's future performance.
- Strategic Goals: Amneal aims to reduce its leverage below 3x by 2028 and has set a revenue target of $4.3 billion to $4.5 billion for 2030 following the Kashiv acquisition, reflecting the company's confidence and strategic positioning for future growth.
See More
Amneal Pharmaceuticals Acquires Kashiv BioSciences, Paving the Way for Biosimilars Integration
- Acquisition Strategy: Amneal announced the acquisition of Kashiv BioSciences for $750 million, structured as a 50-50 mix of cash and equity, positioning Amneal to become the largest affordable medicines company in the U.S. and enhancing its leadership in the biosimilars market.
- Financial Performance: In Q1 2026, Amneal reported net revenues of $723 million, a 4% increase, with adjusted EBITDA of $202 million, up 19%, and EPS of $0.27, up 29%, demonstrating strong financial growth momentum.
- Future Outlook: Management anticipates that by 2030, the combined company's revenue will grow by approximately $1.2 billion, reaching between $4.3 billion and $4.5 billion, with biosimilars revenue expected to be between $1 billion and $1.3 billion, reflecting strong confidence in future market demand.
- Integration Benefits: The acquisition is expected to yield $400 million to $500 million in cumulative financial synergies by eliminating milestone and profit-sharing obligations from prior licensing deals, allowing Amneal to capture full economic benefits from partnered assets and enhance profitability.
See More
U.S. Stocks Rise, Nasdaq Hits Record High
- Strong Market Performance: The S&P 500 index rose by 0.84%, the Dow Jones Industrial Average increased by 0.76%, and the Nasdaq 100 climbed by 1.28%, reflecting robust market sentiment and investor confidence, particularly against the backdrop of better-than-expected corporate earnings.
- Earnings Drive Growth: Companies like GE Vernova, Boeing, and Masco reported Q1 earnings exceeding market expectations, with revenues of $9.34 billion, $1.92 billion, and $5.20 billion respectively, indicating signs of economic recovery and boosting overall market performance.
- Geopolitical Impact: President Trump extended the ceasefire with Iran, and although planned talks were called off, the market's optimism regarding future negotiations has increased investor confidence, with oil prices rising over 2%, potentially exacerbating the global energy crisis.
- Mortgage Applications Surge: U.S. MBA mortgage applications rose by 7.9% in the week ending April 17, with the purchase mortgage sub-index up 10.1%, indicating a rebound in housing demand, while the average 30-year fixed mortgage rate fell to 6.35%, providing better financing conditions for homebuyers.
See More
U.S. Stocks Rise, Nasdaq Hits Record High
- Strong Market Performance: The S&P 500 index rose by 0.65%, the Dow Jones Industrial Average increased by 0.70%, and the Nasdaq 100 climbed by 0.79%, reflecting robust market sentiment, particularly driven by better-than-expected corporate earnings that boosted investor confidence.
- Earnings Drive Growth: Companies like GE Vernova, Boeing, and Masco reported Q1 earnings exceeding expectations, with net sales of $9.34 billion, negative adjusted free cash flow of -$1.45 billion, and $1.92 billion respectively, propelling market gains and enhancing confidence in economic recovery.
- Geopolitical Impact: President Trump announced an indefinite extension of the ceasefire with Iran, and although planned talks were called off, the market remains optimistic about future developments, contributing to a rise in crude oil prices, with WTI crude up over 1%.
- Mortgage Applications Surge: U.S. MBA mortgage applications rose by 7.9% for the week ending April 17, with the purchase mortgage sub-index up 10.1%, indicating signs of recovery in the housing market, while the average 30-year fixed mortgage rate fell to 6.35%.
See More
Amneal Acquires Kashiv BioSciences for $750M, Boosts Revenue Guidance
- Acquisition Scale: Amneal is acquiring Kashiv BioSciences for $750 million in cash and stock, with up to $350 million in milestone payments, significantly enhancing its biosimilars platform at a crucial time as over $300 billion in global biologics are set to lose exclusivity in the next decade.
- Revenue Guidance Increase: The company has raised its 2026 net revenue guidance to $3.05 billion to $3.15 billion, while also adjusting its adjusted EPS guidance from $0.93-$1.03 to $0.95-$1.05, reflecting strong confidence in future growth and robust market demand.
- Growth Potential Expansion: This acquisition extends Amneal's biosimilars business into the 2030s, with expectations to have over 12 commercial biosimilars and more than 20 products in the pipeline by 2030, further diversifying the company's long-term growth profile.
- Financial Performance Improvement: Amneal reported a 4% year-over-year increase in Q1 consolidated net revenue to $723 million, with adjusted diluted EPS rising 29% from $0.21 to $0.27, demonstrating enhanced competitiveness and profitability in the market.
See More
Amneal to Acquire Kashiv, Creating a Global Biosimilars Platform
- Acquisition Agreement: Kashiv BioSciences has entered into a definitive agreement to be acquired by Amneal Pharmaceuticals, expected to close in the second half of 2026, combining Kashiv's expertise in biosimilar development with Amneal's commercial strengths to accelerate the biosimilar pipeline.
- Market Leadership: This acquisition positions Amneal as a fully integrated global leader in biosimilars, leveraging Kashiv's R&D and manufacturing capabilities to drive the launch of high-quality, affordable biologics, thereby enhancing its competitive edge in the U.S. market.
- Strategic Synergy: With a decade-long partnership, the collaboration between Kashiv and Amneal is rooted in a shared commitment to high-quality complex medicines, which is expected to significantly enhance patient access to biosimilars in a rapidly growing market.
- Financial Advisory Support: J.P. Morgan serves as Kashiv's financial advisor while Holland & Knight LLP provides legal counsel, ensuring the transaction's smooth execution and reflecting market confidence in the future growth potential of the biosimilars sector.
See More
Amneal Pharmaceuticals Q1 Earnings Preview
- Earnings Announcement: Amneal Pharmaceuticals (AMRX) is set to release its Q1 2026 earnings on May 1 before market open, with consensus EPS estimate at $0.17, reflecting a 19% year-over-year decline, while revenue is projected at $716.78 million, indicating a 3.1% year-over-year increase.
- Historical Performance: Over the past two years, AMRX has exceeded EPS estimates 88% of the time and revenue estimates 75% of the time, demonstrating a degree of stability and reliability in its financial performance.
- Estimate Adjustments: In the last three months, there have been no upward revisions to EPS estimates, with three downward adjustments, while revenue estimates also saw no upward revisions and two downward adjustments, indicating a cautious market outlook on the company's future performance.
- Strategic Goals: Amneal aims to reduce its leverage below 3x by 2028 and has set a revenue target of $4.3 billion to $4.5 billion for 2030 following the Kashiv acquisition, reflecting the company's confidence and strategic positioning for future growth.
See More
Amneal Pharmaceuticals Acquires Kashiv BioSciences, Paving the Way for Biosimilars Integration
- Acquisition Strategy: Amneal announced the acquisition of Kashiv BioSciences for $750 million, structured as a 50-50 mix of cash and equity, positioning Amneal to become the largest affordable medicines company in the U.S. and enhancing its leadership in the biosimilars market.
- Financial Performance: In Q1 2026, Amneal reported net revenues of $723 million, a 4% increase, with adjusted EBITDA of $202 million, up 19%, and EPS of $0.27, up 29%, demonstrating strong financial growth momentum.
- Future Outlook: Management anticipates that by 2030, the combined company's revenue will grow by approximately $1.2 billion, reaching between $4.3 billion and $4.5 billion, with biosimilars revenue expected to be between $1 billion and $1.3 billion, reflecting strong confidence in future market demand.
- Integration Benefits: The acquisition is expected to yield $400 million to $500 million in cumulative financial synergies by eliminating milestone and profit-sharing obligations from prior licensing deals, allowing Amneal to capture full economic benefits from partnered assets and enhance profitability.
See More
U.S. Stocks Rise, Nasdaq Hits Record High
- Strong Market Performance: The S&P 500 index rose by 0.84%, the Dow Jones Industrial Average increased by 0.76%, and the Nasdaq 100 climbed by 1.28%, reflecting robust market sentiment and investor confidence, particularly against the backdrop of better-than-expected corporate earnings.
- Earnings Drive Growth: Companies like GE Vernova, Boeing, and Masco reported Q1 earnings exceeding market expectations, with revenues of $9.34 billion, $1.92 billion, and $5.20 billion respectively, indicating signs of economic recovery and boosting overall market performance.
- Geopolitical Impact: President Trump extended the ceasefire with Iran, and although planned talks were called off, the market's optimism regarding future negotiations has increased investor confidence, with oil prices rising over 2%, potentially exacerbating the global energy crisis.
- Mortgage Applications Surge: U.S. MBA mortgage applications rose by 7.9% in the week ending April 17, with the purchase mortgage sub-index up 10.1%, indicating a rebound in housing demand, while the average 30-year fixed mortgage rate fell to 6.35%, providing better financing conditions for homebuyers.
See More
U.S. Stocks Rise, Nasdaq Hits Record High
- Strong Market Performance: The S&P 500 index rose by 0.65%, the Dow Jones Industrial Average increased by 0.70%, and the Nasdaq 100 climbed by 0.79%, reflecting robust market sentiment, particularly driven by better-than-expected corporate earnings that boosted investor confidence.
- Earnings Drive Growth: Companies like GE Vernova, Boeing, and Masco reported Q1 earnings exceeding expectations, with net sales of $9.34 billion, negative adjusted free cash flow of -$1.45 billion, and $1.92 billion respectively, propelling market gains and enhancing confidence in economic recovery.
- Geopolitical Impact: President Trump announced an indefinite extension of the ceasefire with Iran, and although planned talks were called off, the market remains optimistic about future developments, contributing to a rise in crude oil prices, with WTI crude up over 1%.
- Mortgage Applications Surge: U.S. MBA mortgage applications rose by 7.9% for the week ending April 17, with the purchase mortgage sub-index up 10.1%, indicating signs of recovery in the housing market, while the average 30-year fixed mortgage rate fell to 6.35%.
See More
Amneal Acquires Kashiv BioSciences for $750M, Boosts Revenue Guidance
- Acquisition Scale: Amneal is acquiring Kashiv BioSciences for $750 million in cash and stock, with up to $350 million in milestone payments, significantly enhancing its biosimilars platform at a crucial time as over $300 billion in global biologics are set to lose exclusivity in the next decade.
- Revenue Guidance Increase: The company has raised its 2026 net revenue guidance to $3.05 billion to $3.15 billion, while also adjusting its adjusted EPS guidance from $0.93-$1.03 to $0.95-$1.05, reflecting strong confidence in future growth and robust market demand.
- Growth Potential Expansion: This acquisition extends Amneal's biosimilars business into the 2030s, with expectations to have over 12 commercial biosimilars and more than 20 products in the pipeline by 2030, further diversifying the company's long-term growth profile.
- Financial Performance Improvement: Amneal reported a 4% year-over-year increase in Q1 consolidated net revenue to $723 million, with adjusted diluted EPS rising 29% from $0.21 to $0.27, demonstrating enhanced competitiveness and profitability in the market.
See More
Amneal to Acquire Kashiv, Creating a Global Biosimilars Platform
- Acquisition Agreement: Kashiv BioSciences has entered into a definitive agreement to be acquired by Amneal Pharmaceuticals, expected to close in the second half of 2026, combining Kashiv's expertise in biosimilar development with Amneal's commercial strengths to accelerate the biosimilar pipeline.
- Market Leadership: This acquisition positions Amneal as a fully integrated global leader in biosimilars, leveraging Kashiv's R&D and manufacturing capabilities to drive the launch of high-quality, affordable biologics, thereby enhancing its competitive edge in the U.S. market.
- Strategic Synergy: With a decade-long partnership, the collaboration between Kashiv and Amneal is rooted in a shared commitment to high-quality complex medicines, which is expected to significantly enhance patient access to biosimilars in a rapidly growing market.
- Financial Advisory Support: J.P. Morgan serves as Kashiv's financial advisor while Holland & Knight LLP provides legal counsel, ensuring the transaction's smooth execution and reflecting market confidence in the future growth potential of the biosimilars sector.
See More
